Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Oregon Health and Science University2 个研究点分布在 1 个国家目标入组 40 人开始时间: 2026年5月5日最近更新: 2026年5月20日

试验速览

阶段: 4 期
状态: 招募中
发起方: Oregon Health and Science University
入组人数: 40
试验地点: 2

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 90 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.
•Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.
•Patient willing to consent for the study and undergo the study procedures.

排除标准

•Severe aortic stenosis or sub-aortic obstruction
•Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
•History of LVEF <30%.
•Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.
•Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.
•Documented history of current obstructive coronary artery disease (> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.

研究者

发起方

Oregon Health and Science University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Ahmad Masri

Associate Professor

Oregon Health and Science University

研究点 (2)

Loading locations...

相似试验

招募中

不适用

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

NCT07383025Bristol-Myers Squibb200

招募中

3 期

A study of aficamten (CK-3773274) in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy

2024-511377-30-00Cytokinetics Inc.4

招募中

3 期

A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA)

2023-505797-15-00Cytokinetics Inc.175

尚未招募

4 期

Switching From Restasis to TRYPTYRDry Eye

NCT07267299Southern College of Optometry100

已完成

不适用

Mavacamten in Adult Patients With Obstructive Hypertrophic CardiomyopathyHypertrophic Cardiomyopathy (HCM)Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT07529938Chinese Academy of Medical Sciences, Fuwai Hospital222